Hikma's US generics sales drive first half
This article was originally published in Scrip
Executive Summary
Hikma Pharmaceuticals of Jordan says its strategy of expansion and diversification has led to it reporting an increase in revenue for the first half ended 30 June to $357.7 million (+11%) and a rise in adjusted operating profit to $73.2 million (+20%).